StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
GDS.PA$11.10-1.77%
Fair $11.10+0.0%

GDS.PA

Ramsay Générale de Santé SA

Healthcare / Medical Care FacilitiesParis

$11.10

-0.20 (-1.77%)

Fairly Valued+0.0%Fair Value $11.10Fund rank 23/100 · Data gapFallback financials|
SA 34/D
F-Score: 3/9
High DebtMargin CompressionLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 25% · confianza 25%

FCF escenarios

weak_data · normalized FCF $426.7M · quality 33.0/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 51/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

34/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 3unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 3.57, above the 2.0 threshold Operating margin has declined for 3 consecutive years ROE is -4.7%, below the 5% threshold
Thesis & Journal · GDS.PALocal privado en este navegador · Ramsay Générale de Santé SA
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.2B

P/E

N/A

•

EV/EBITDA

8.2x

↓

ROE

-4.7%

↓

Gross Margin

77.9%

↑

Debt/Equity

3.57

↑
52-Week Range$11
$9$12

TradingView lightweight chart

GDS.PA price, volumen y niveles de valoración

Último $11.10Periodo -40.2%
Fair value: $11.10

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+6.8%

FCF CAGR

+100.0%

FCF margin

10.5%

FCF / Net income

-10.18x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $5.24B · net income $-54.1M · FCF $550.9M

2022-FY → 2025-FY

Gross margin

77.9%-1.4% pts

Operating margin

3.6%-3.3% pts

Net margin

-1.0%-3.8% pts

FCF margin

10.5%+8.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$5.24B$5.24B$5.01B$4.70B$4.30B
Net Income$-54.1M$-54.1M$-53.9M$49.4M$118.4M
EBITDA$599.7M$599.7M$562.9M$645.6M$677.1M
EPS——-0.490.451.07
Gross Margin77.9%77.9%78.7%79.2%79.3%
Operating Margin3.6%3.6%3.7%4.7%6.8%
Net Margin-1.0%-1.0%-1.1%1.1%2.8%
Balance Sheet
Debt/Equity3.573.573.403.333.27
Current Ratio0.770.77———
Cash Flow
Free Cash Flow$550.9M$550.9M$418.3M$426.7M$68.9M
Returns
ROE-4.7%-4.7%-4.5%4.0%9.8%
Valuation
P/E———45.3320.93
EV/EBITDA8.248.249.689.379.31
P/B1.071.071.461.812.04
Growth & Yield
Revenue Growth4.7%4.7%6.5%9.3%—
EPS Growth——-208.9%-57.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +2.8%

Total return

+2.8%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.49 → n/d

Residual

+2.8%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+2.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.